Using novel tools such as kinematic gait analysis, we have validated several neuropathic and peripheral neuroinflammatory pain models to support the development of therapies which target these conditions.
We now offer a hind limb ischemia model of peripheral stroke, augmenting our existing selection of vascular stroke models, available study paradigms and types of CNS injury.
Charles River now offers MALDI-TOF mass spectrometry for animals or samples submitted to 360 Diagnostics™ for microbiological analysis.
Maintaining the security and integrity of your cell banks is our priority. We store cell banks at -70 °C or in vapor-phase liquid nitrogen in a controlled-access area and take a multilayered approach to ensure the security and performance of the cell storage facility.
The FDA recently published final versions of three key biosimilar guidance documents and followed them in May with a revised draft guidance, which references the issue of interchangeability.
Charles River Avian Vaccine Services is proud to announce the opening of our new SPF egg incubation facility in Spain.
The comprehensive in vitro proarrhythmia assay (CIPA) is expected to change the landscape of preclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk.
Recordings from our recent webinar series on developmental, reproductive and juvenile toxicology are now available on-demand. In the series, our experts discuss customary study designs using a range of animal models, as well as non-standard techniques and endpoints that enhance the value of study data.
Charles River Sherbrooke now offers imaging within our toxicology study designs through our partnership with the Sherbrooke Molecular Imaging Center (CIMS).
We are excited to announce our newly available 18-plex bead-based cytokine panel for preclinical species with a high potential for translation to human.